EMA Application withdrawn: Plivensia (sirukumab) — Janssen-Cilag International NV

View source ↗

Summary

The EMA withdrew the application for Plivensia (sirukumab) by Janssen-Cilag International NV for rheumatoid arthritis indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Plivensia (sirukumab)

Snippet

Status: Application withdrawn. Therapeutic area: Arthritis, Rheumatoid. MAH: Janssen-Cilag International NV. Decision date: 10/11/2017